Health Care
Immutep Limited (IMM)
Immutep Limited (ASX: IMM) is a biopharmaceutical company headquartered in Australia, specializing in immunotherapy for cancer and auto-immune diseases. It operates globally with research alliances and trials in the US and Europe. Key product is pep005, an immune-stimulating agent, and ipilimumab combination therapies. IMM has no commercial products yet, focusing on clinical trials.
Market Cap
A$567M
Shares on Issue
N/A
Price Chart
AI Analysis
IMM's current business position is heavily reliant on successful clinical trial outcomes, with recent performance marked by funding rounds to support its pipeline, notably the ACTIVATE trial for its lead candidate, pep005. As of its latest update, the company has sufficient cash to meet near-term trial obligations but remains pre-revenue with a market cap of A$567M, reflecting its speculative, small-cap nature.
Growth outlook hinges on positive trial data for pep005, particularly in melanoma and other cancer types. Upcoming catalysts include interim trial results and potential partnerships. Strategically, IMM aims to leverage its immunotherapy platform for broader oncology applications, though success is not guaranteed.
Bull Case
- • Successful pep005 trial data leads to strategic partnership or licensing agreement, significantly boosting valuation.
- • Broader adoption of immunotherapy in cancer treatment benefits IMM's pipeline attractiveness.
- • Pipeline expansion through successful development of combination therapies with ipilimumab.
Bear Case
- • Negative or inconclusive clinical trial results for pep005, jeopardizing its development pipeline.
- • Increased competition in the immunotherapy space from larger, more established biopharma companies.
- • Funding challenges requiring dilutive equity raises to support trial progression.
Recent Announcements
Change in substantial holding
Immutep Quarterly Activities Report and Appendix 4C
🚨 Price SensitiveImmutep, a Commitments Test Entity on ASX reporting quarterly activities with significant developments in their immunotherapy research for cancer treatment.
FAQs
What does IMM do?
IMM develops immunotherapies for cancer, notably pep005, in clinical trials globally.
Is IMM a good investment?
IMM offers high-risk, high-reward potential. Success in trials could lead to significant gains, but biotech failures are common. Suitability depends on investor risk tolerance and belief in IMM's pipeline.
What drives IMM's share price?
Trial outcomes, partnership announcements, funding news, and broader biotech sector trends primarily drive IMM's share price.
Key Metrics
Related Stocks
Health Care
CSLCSL Ltd
A$181.24
-27.3% 1Y
CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.
Health Care
PNVPolynovo Ltd
A$0.99
-13.1% 1Y
Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.
Health Care
1ADAdalta Limited
A$0.01
-25.6% 1Y
Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.